Compare AbbVie Inc (ABBV) vs Nucor Corporation (NUE) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Nucor (NUE) trades at $272.63, up 0.23% on the day, with a bullish technical outlook supported by moving averages and strong resistance near $280. Recent Q2 2026 earnings beat expectations with EPS of $4.84 versus $4.46, driven by record steel shipments and higher prices. Revenue trends show recovery from 2024 lows, with 2026 projections at $36.1B. The stock is near its consensus price target of $279.63, with analyst sentiment leaning bullish (59% buy ratings).

Outlook: Nucor benefits from resilient steel demand and operational efficiency, but faces risks from tariff policies and cyclical industry pressures. The current P/E of 21.76 is reasonable given earnings growth, though net margins have compressed from 2022 peaks. Investors should monitor Q3 2026 results against the $5.72 EPS estimate for continued momentum.